Annals of Indian Academy of Neurology
  Users Online: 1340 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size

Table of Contents
LETTER TO THE EDITOR
Year : 2011  |  Volume : 14  |  Issue : 2  |  Page : 140
 

'Beta-interferons' and 'oligoclonal bands' in multiple sclerosis in India


Department of Neurology, Command Hospital, Kolkata - 700 027, India

Date of Web Publication7-Jul-2011

Correspondence Address:
K M Hassan
Department of Neurology, Command Hospital, Alipore, Kolkata - 700 027
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0972-2327.82817

Rights and Permissions

 



How to cite this article:
Hassan K M. 'Beta-interferons' and 'oligoclonal bands' in multiple sclerosis in India. Ann Indian Acad Neurol 2011;14:140

How to cite this URL:
Hassan K M. 'Beta-interferons' and 'oligoclonal bands' in multiple sclerosis in India. Ann Indian Acad Neurol [serial online] 2011 [cited 2019 Nov 22];14:140. Available from: http://www.annalsofian.org/text.asp?2011/14/2/140/82817


Sir,

The short communication on study by Gupta et al., titled "Beta-interferons in multiple sclerosis: A single centre experience in India", published in Ann Indian Acad Neurol 2010;13:132-5, is a landmark study from India for several reasons. [1]

  1. It is the first study from India documenting response to therapy in multiple sclerosis (MS) with β-interferons. The annualized relapse rate was reduced to zero, except in three patients out of 16, followed up for a mean period of 2.25 years. While no firm conclusions from this study can be drawn on efficacy outcomes of interferon beta-1a once a week (Avonex) versus interferon beta-1b every other day (Betaferon) on relapsing remitting multiple sclerosis (RRMS), it showed the only patient of secondary progressive multiple sclerosis (SPMS), after one relapse in the first year of therapy, being relapse free on interferon beta-1b every other day (Betaferon) followed for a mean period of 1.5 years.

    Clinical trials such as EVIDENCE and INCOMIN have demonstrated greater efficacy for higher and more frequently dosed interferon beta-1a three times a week /interferon beta-1b every other day versus interferon beta-1a once a week. Relapse and MRI benefits have been demonstrated with interferon beta-1a three times a week/interferon beta-1b every other day in SPMS patients. [2] Clinical trials such as REGARD and BEYOND did not demonstrate any difference in relapse for interferon beta-1a three times a week or interferon beta-1b every other day compared to galtiramer acetate. [2]

    Personal experience with β-interferons in MS from three tertiary care centers of the Armed Forces is nearly in keeping with the current study. However, in my personal opinion, treatment failure was a major concern with interferon beta-1a once a week in some of the cases (unpublished personal observation). Whether these patients would do better on interferon beta-1a three times a week/interferon beta-1b every other day alone; would be candidates for galtiramer acetate; or would be candidates for natalizumab alone or in combination, remains an open question.
  2. This study has also established that Indian MS patients tolerate β-interferons well.
  3. It is also noteworthy that nearly 85% patients with MS in this series from India have been demonstrated to have oligoclonal bands (OCBs) in cerebrospinal fluid (CSF), [1] which is in keeping with the Caucasian MS. [3] Earlier studies from India have documented lower incidence of OCBs in CSF (20-30%), largely because of greater proportion of opticospinal MS in those series, [4] which are now recognized to be part of Neuromyelitis Optica spectrum disorders. [3]

    The presence of OCBs in CSF can be used as evidence for dissemination in space with lesser stringent criteria on MRI. It is also a predictor of future relapse in clinically isolated syndrome or clinically definite MS. [5] Hence, OCBs in CSF may play an important role in therapeutic decision making in Indian patients of MS.
  4. Further, the clinical profile of MS in this study was closer to the "Western" MS, perhaps because of application of stringent McDonald's criteria for diagnosing MS in the current study. [1]


With routine application of McDonald's criteria for diagnosing MS it is likely that more "Western type" cases of MS will be diagnosed in India. The role of NMO-IgG in opticospinal demyelinating disorders is being increasingly recognized. [3] Differentiating the two is important from prognostic and therapeutic standpoints, and for financial reasons in resource poor settings.

 
   References Top

1.Gupta Salil, Varadarajulu R, Ganjoo RK. Beta-interferons in multiple sclerosis: A single centre experience in India. Ann Ind Acad Neurol 2010;13:132-5.  Back to cited text no. 1
    
2.Coyle PK. Disease-modifying agents in multiple sclerosis. Ann Ind Acad Neurol 2009;12:273-82.  Back to cited text no. 2
    
3.Jacob A, Boggild M. Neuromyelitis optica. Ann Ind Acad Neurol 2007;10:231-9.  Back to cited text no. 3
    
4.Jain S, Maheshwari MC. Multiple sclerosis: Indian experience in the last thirty years. Neuroepidemiology 1985;4:96-107.  Back to cited text no. 4
    
5.Rammohan KW. Cerebrospinal fluid in multiple sclerosis. Ann Ind Acad Neurol 2009;12:246-53.  Back to cited text no. 5
    




 

Top
Print this article  Email this article

    

 
   Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (225 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed1813    
    Printed70    
    Emailed1    
    PDF Downloaded74    
    Comments [Add]    

Recommend this journal